{"schema_version":"secwatch.filing_event.v1","accession":"0001013762-25-003401","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.544952+00:00","generated_at":"2026-05-24T03:58:31.564248+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"INmune Bio FY2024 net loss $42.1M; AD02 top-line data expected June 2025","bullets":["Net loss $42.1M vs $30.0M in FY2023; R&D expenses rose to $33.2M from $20.3M.","Cash and equivalents $20.9M as of Dec 31, 2024; $22.9M shares outstanding.","Completed $27.5M equity offering (incl. ~3.9M warrants) and repaid Silicon Valley Bank loan.","AD02 Phase 2 Alzheimer's trial fully enrolled (208 patients); top-line cognitive results due June 2025.","CORDStrom planning BLA filing in RDEB in 2025/early 2026, eligible for Priority Review Voucher."],"urls":{"canonical":"https://secwatch.observer/filing/0001013762-25-003401","json":"https://secwatch.observer/filing/0001013762-25-003401.json","markdown":"https://secwatch.observer/filing/0001013762-25-003401.md","text":"https://secwatch.observer/filing/0001013762-25-003401.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000101376225003401/0001013762-25-003401-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000101376225003401/ea0235584-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:58:31.564248+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}